A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To evaluate disease control rate (DCR) of S-1 in combination with gemcitabine in patients with advanced biliary tract cancer

Secondary Objectives:

* To evaluate overall response rate (ORR)
* To evaluate progression-free survival (PFS)
* To evaluate overall survival (OS)
* To assess the safety profile

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

NCT04172402

Advanced Biliary Tract Cancer

COMPLETED PHASE2

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

NCT05822453

Biliary Tract Carcinoma

NOT_YET_RECRUITING PHASE2

Gemcitabine and S-1 for Advanced Biliary Tract Cancer

NCT02146703

Biliary Tract Neoplasm

COMPLETED PHASE2

Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract

NCT00201305

Biliary Tract Disease

COMPLETED PHASE2

Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer

NCT01291615

Biliary Tract Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Biliary Tract Cancer(BTC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S-1/Gemcitabine

single-arm

Group Type EXPERIMENTAL

S-1/Gemcitabine

Intervention Type DRUG

Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

S-1/Gemcitabine

Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TS-1/Gemmis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.histologically confirmed biliary tract carcinoma (including intrahepatic bile duct, extrahepatic bile duct, gallbladder, and ampulla of vater);
* 2.metastatic or unresectable disease;
* 3.no history of chemotherapy or radiotherapy for biliary tract cancer;
* 4.presence of at least one measurable tumor lesion which is defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) ≥20 mm using conventional techniques or ≥10 mm with spiral CT and MRI; measurable lymph nodes must be ≥15 mm in the short axis;
* 5.adequate hematopoietic function which is defined as below:

1. hemoglobin level ≥ 9 g/dL;
2. absolute neutrophil count (ANC) ≥ 1,500/mm3;
3. platelet count ≥ 100,000/mm3;
* 6.adequate hepatic function which is defined as below:

1. total bilirubin ≤ 1.5 times upper limit of normal (ULN) and \< 2 mg/dL, or total bilirubin \< 3 mg/dL if biliary drainage was performed;
2. Alanine aminotransferase (ALT) ≤ 3 x ULN or ALT ≤ 5 x ULN in the presence of liver metastasis;
* 7.adequate renal function: creatinine clearance rate (CCr) ≥ 60 mL/min ((based upon 24-hour urine collection or calculated by Cockroft-Gault formula);
* 8.age of 20 years or above;
* 9.ECOG performance status 0-1;
* 10.life expectancy of at least 12 weeks;
* 11.ability to take oral medication;
* 12.ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

* 1.other malignancy within the past 5 years except for adequately treated basal or squamous cell skin cancer or cervical cancer in situ;
* 2.history or known presence of brain metastasis;
* 3.presence of grade 2 or above ascites or pleural effusion;
* 4.presence of grade 2 or above diarrhea;
* 5.presence of mental disease or psychotic manifestation;
* 6.active or uncontrolled infection;
* 7.significant medical conditions that is contraindicated to study medication or render patient at high risk from treatment complications based on investigator's discretion;
* 8.pregnant women or nursing mothers, or positive pregnancy test for women of childbearing potential. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No